Author Question: A new psychoactive drug has completed phase three of the Food and Drug Administration's drug ... (Read 138 times)

panfilo · **on:** Jul 19, 2018

A new psychoactive drug has completed phase three of the Food and Drug Administration's drug approval process and has been granted a labeled indication. A labeled indication denotes the:

A) Recommended doses and routes of the drug
B) Use of the drug in the treatment of specific illnesses
C) Most common adverse effects that have been observed to this point in testing
D) Information that must appear on consumer packaging of the drug

Question 2

The nurse caring for a client taking clozapine is monitoring the client's blood work. The nurse should prioritize assessment of the client's:

A) Cardiac enzymes
B) Blood urea nitrogen and creatinine
C) White blood cell count
D) Liver function tests

flannelavenger · **Reply #1 on:** Jul 19, 2018

Answer to Question 1

Ans: B

Feedback:

After phase 3, the FDA grants a labeled indication to a drug for use in a specific illness.

Answer to Question 2

Ans: C
Feedback:
Use of clozapine requires weekly monitoring of white blood cell (WBC) counts to assess for agranulocytosis. Clozapine suppresses the development of WBCs in 1 to 2 of all clients who take it. If WBC levels decrease significantly from baseline, immediate discontinuation of clozapine is recommended. Clients never should use clozapine with other agents that suppress WBC production, such as carbamazepine.